Theme 10 Disease stratification and phenotyping of patients
- 31 October 2019
- journal article
- research article
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 20 (sup1) , 289-300
Abstract
Background: MND is a progressive neurodegenerative disease characterised by death of upper and lower motor neurons, leading to progressive weakness of the bulbar, limb, thoracic and abdominal muscles. MND has a fairly stereotypical course, with death from respiratory failure occurring 2-4 years after symptom onset in most cases ( 1 ForsgrenL , AlmayBG , HolmgrenG , et al. Acta Neurol Scand. 1983;68:20–29. [Crossref], [PubMed], [Web of Science ®] , [Google Scholar] ). Making the diagnosis of MND can be straightforward when key clinical criteria are met; however, at first presentation, rarely do patients meet these criteria, neurological changes may be subtle and disease progression slow. Thus, diagnosis poses a significant challenge, particularly in general practice, where patients are most likely to first present. Not surprisingly, there is usually a delay of 10-18 months between symptom onset and MND diagnosis ( 2 ChiòA , MoraG , CalvoA , et al. Neurology. 2009; 72(8):725–31. [Crossref], [PubMed], [Web of Science ®] , [Google Scholar] ). Importantly, early assessment by a neurologist is associated with a shorter time to MND diagnosis ( 3 MitchellJD , CallagherP , GardhamJ , et al. Amyotroph Lateral Scler. 2010;11(6):537–41. [Taylor & Francis Online], [Web of Science ®] , [Google Scholar] ), which has significant implications for access to healthcare, including Riluzole and multidisciplinary clinics, which improve survival ( 4 RooneyJ , ByrneS , HeverinM , et al. J Neurol Neurosurg Psychiatry. 2015;86(5):496–501. [Crossref], [PubMed], [Web of Science ®] , [Google Scholar] ). Although delay in diagnosis is well documented, there have been no studies that have sought to identify factors associated with time to diagnosis, thereby enabling targeted implementation of a public health intervention. Objectives: To characterise the clinical factors that influence time to diagnosis of MND. Methods: 112 patients with MND attending the Southern Adelaide MND Clinic enrolled between January 2016 - 2018 were retrospectively recruited in to a cohort study. Information pertaining to the patient’s demographics and their journey to diagnosis collected by a specialist physician and stored in the Australian MND Registry during clinic review were analysed to identify factors associated with time to diagnosis. Results: Mean time to diagnosis was 13 ± 1 months (range 1 – 38 months) from symptom onset. 41% of patients were classified as having fast disease progression; compared to those with slow disease progression, these patients were diagnosed earlier (8 ± 1 months vs 16 ± 2 months) (p < 0.0001, t = 34.6, df =220), were less likely to undergo multiple specialist opinions prior to referral to a neurologist (53% vs 73%) (p < 0.05, Chi-squared = 9.5, df =1), and were more disabled at time of diagnosis (mean ALSFRS-R 33 ± 5 vs ALSFRS-R 41 ± 5) (p < 0.0001, t = 12.4, df =220). Discussion and conclusions: Fast disease progression identifies a dichotomy of MND patients diagnosed earlier, although more disabled at diagnosis, likely mediated by a more efficient referral process. A greater awareness of MND is required to shorten time to diagnosis.Keywords
This publication has 24 references indexed in Scilit:
- Biomarkers of Metabolism in Amyotrophic Lateral SclerosisFrontiers in Neurology, 2019
- Hypermetabolism in ALS is associated with greater functional decline and shorter survivalJournal of Neurology, Neurosurgery & Psychiatry, 2018
- Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trialsJournal of Neurology, Neurosurgery & Psychiatry, 2017
- Neurofilament markers for ALS correlate with extent of upper and lower motor neuron diseaseNeurology, 2017
- Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient dataClinical Neurophysiology, 2016
- A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern IrelandJournal of Neurology, Neurosurgery & Psychiatry, 2014
- Stages of pTDP‐43 pathology in amyotrophic lateral sclerosisAnnals of Neurology, 2013
- Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) – a 20-year review: Can we do better?Amyotrophic Lateral Sclerosis, 2010
- Epidemiology of ALS in ItalyNeurology, 2009
- Epidemiology of motor neuron disease in northern SwedenActa Neurologica Scandinavica, 1983